Drugs / Afalaza
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01716104 | Nov 2012 → Nov 2016 | benign prostatic hyperplasia | Materia Medica Holding | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Afalaza | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01716104 ↗ |
| Modality | Protein / enzyme biologic | “Derived by technological treatment of antibodies to prostate-specific antigen (PSA) and endothelial nitric oxide synthase (eNOs), Afalaza was previously proved to modulate its...” PMID 30680237 ↗ Dec 2018 |